The specificity of detection of cancer-specific mutations by plasma NGS was demonstrated by the detection of a mutation in 85% (6/7) of other cancer cases, including pathogenic TP53 mutations in 71% (5/7) of cases (Supplementary Table 2). Here, TP53 is linked to cancer.